Fierce Pharma

MAY 22, 2024

Otsuka Pharmaceutical is packing up an Alzheimer’s disease med after a phase 3 study failed to move the needle on m | Otsuka Pharmaceutical is packing up an Alzheimer’s disease med after a phase 3 study failed to move the needle on measures of agitation associated with dementia.

Pharmaceutical 322

Pharmaceutical 322

Fierce Pharma

AUGUST 14, 2024

Johnson & Johnson and Roche are at the top of S&P Global’s pharmaceutical industry power ratings, which assess the strength of the world’s top 17 drugmakers. | Johnson & Johnson and Roche are at the top of S&P Global’s pharmaceutical industry power ratings, which assess the strength of the world’s top 17 drugmakers.

Biopharma 325

Biopharma Pharmaceutical 325

Fierce Pharma

JULY 6, 2023

Less than two months into its "Pivot to Growth" strategy under a new CEO, Israeli-American generics giant Teva Pharmaceutical could be weighing a major shake-up of its key drug ingredients business | Teva is looking at strategic options for its active pharmaceutical ingredient unit, with a potential sale on the table, BNN Bloomberg and Benzinga (..)

Sales 357

Sales Pharmaceutical 357

Fierce Pharma

OCTOBER 28, 2024

Novartis and Apellis Pharmaceuticals have rolled out detailed data on iptacopan and pegcetacoplan, respectively, as they race for the prize in a type of rare kidney disease. Novartis and Apellis dropped new data on their respective meds, iptacopan and pegcetacoplan, in the rare kidney disease C3 glomerulopathy.

Pharmaceutical 328

Pharmaceutical 328

Fierce Pharma

OCTOBER 15, 2024

Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it could prolong patients’ lives in extensive-stage small cell lung cancer (ES- | Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it could prolong patients’ lives (..)

Pharmaceutical 311

Pharmaceutical Marketing Patients 311

Fierce Pharma

JANUARY 16, 2024

Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FD | Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval came more than two months ahead of the FDA's March 30 decision date.

FDA 306

FDA Pharmaceutical 306

Fierce Pharma

JUNE 21, 2024

Cystic fibrosis (CF) patients and their families in England can rest a little easier this week, thanks to an extended long-term reimbursement deal inked by Vertex Pharmaceuticals and the country’s | Cystic fibrosis (CF) patients and their families in England can rest a little easier this week, thanks to an extended long-term reimbursement deal inked (..)

Pharmaceutical 310

Pharmaceutical Patients 310

Fierce Pharma

JUNE 24, 2024

In one of the most closely watched biotech trial readouts of the year, Alnylam Pharmaceuticals said its RNA interference drug reduced the risk of death or recurrent cardiovascular events in patient | In one of the most closely watched biotech trial readouts of the year, Alnylam Pharmaceuticals said its RNA interference drug reduced the risk of death (..)

Pharmaceutical 319

Pharmaceutical Patients 319

Fierce Pharma

OCTOBER 14, 2024

The FDA’s rejection of Vanda Pharmaceuticals’ stomach disease candidate has done little to dampen the enthusiasm of England’s Cycle Pharmaceuticals to acquire the Washington D.C.-based based company. |

FDA 277

FDA Pharmaceutical Pharma 277

Fierce Pharma

MAY 6, 2024

Amneal Pharmaceuticals has agreed to pay $272.5 million to settle approximately 900 lawsuits brought by state, local and Native American jurisdictions claiming that the New Jersey generics producer | Amneal Pharmaceuticals has agreed to pay $272.5

Pharmaceutical 306

Pharmaceutical 306

Fierce Pharma

DECEMBER 21, 2023

As Vertex Pharmaceuticals and CRISPR Therapeutics lay the groundwork for the launch of their CRISPR-based gene-editing therapy Casgevy, one doctor who treats sickle cell disease patients is already | As Vertex Pharmaceuticals and CRISPR Therapeutics lay the groundwork for the launch of their world-first CRISPR-based gene therapy Casgevy, one doctor (..)

Doctors 323

Doctors Pharmaceutical Patients 323

Fierce Pharma

MAY 8, 2024

the House Committee on Oversight and Accountability chairman argued that China’s influence over global pharmaceutical supply chains constitutes an act of economic warfare against the United States. Amid a U.S. | In a letter to FDA Commissioner Robert Califf, M.D.,

FDA 328

FDA Pharmaceutical 328

Fierce Pharma

NOVEMBER 22, 2023

In a lawsuit filed in Delaware federal court Monday, AbbVie accused Sandoz, Hetero Labs, Aurobindo Pharma, Intas Pharmaceuticals and Sun Pharmaceutical of trying to sidestep dozens of patents protecting Rinvoq through the next decade.

Pharmaceutical 312

Pharmaceutical Pharma Marketing 312

Fierce Pharma

NOVEMBER 7, 2024

After an activist investor revolted against the leadership team at Aurinia Pharmaceuticals, the CEO in question is resorting to restructuring.

Pharmaceutical 279

Pharmaceutical 279

Fierce Pharma

APRIL 22, 2024

The prospects for Vanda Pharmaceuticals’ 10-year-old circadian rhythm drug Hetlioz have grown that much dimmer after the U.S. | The prospects for Vanda Pharmaceuticals’ 10-year-old circadian rhythm drug Hetlioz have grown that much dimmer after the U.S.

Prospecting 278

Prospecting Pharmaceutical 278

Fierce Pharma

JUNE 21, 2024

In this week’s episode of “The Top Line,” Fierce Pharma’s Zoey Becker sits down with Bobby Sheng, the CEO of Bora Pharmaceuticals, to discuss the concept of “friend-shoring” in drug manufacturing.<

Manufacturing 279

Manufacturing Pharmaceutical 279

Fierce Pharma

JANUARY 4, 2024

Investment giant Bain Capital is weighing a potential sale of its Dutch antibiotics and active pharmaceutical ingredients (API) specialist Centrient Pharmaceuticals, which could be valued as high as €1 billion ($1.09 billion), Bloomberg reported Wednesday, citing people close to the talks.

Manufacturing 278

Manufacturing Sales Pharmaceutical 278

Fierce Pharma

JANUARY 7, 2024

Less than six months after Ligand Pharmaceuticals swooped in to buy Novan’s assets following the latter company’s bankruptcy, the purchase has paid off with an FDA approval. | Less than six months after Ligand Pharmaceuticals swooped in to buy Novan’s assets following the latter company’s bankruptcy, the purchase has paid off with an FDA approval. (..)

FDA 272

FDA Pharmaceutical 272

Fierce Pharma

OCTOBER 18, 2023

EVP, Global Head of Research and Development at Jazz Pharmaceuticals | Learn more about how Jazz Pharmaceuticals harnesses the therapeutic potential of cannabinoids to drive patient-centric innovation By Robert Iannone, M.D.,

Pharmaceutical 289

Pharmaceutical Patients 289

Fierce Pharma

AUGUST 8, 2024

A year after it was hit with a rejection from the FDA, Citius Pharmaceuticals has scored an approval for Lymphir to treat cutaneous T-Cell Lymphoma.

FDA 303

FDA Pharmaceutical 303

Fierce Pharma

OCTOBER 28, 2024

Earlier this year, EyePoint Pharmaceuticals’ drug-device combo Duravyu missed the mark in a non-proliferative diabetic retinopathy (NPDR) study, raising doubts about the product’s potential in seve | EyePoint released new diabetic macular edema data Monday that a Mizuho Securities analyst described as "very promising."

Leads 294

Leads Pharmaceutical 294

European Pharmaceutical Review

NOVEMBER 21, 2024

The post <em>European Pharmaceutical Review </em> Issue 5 2024 appeared first on European Pharmaceutical Review. Register your details to access this exclusive content!

Pharmaceutical 97

Pharmaceutical Consulting Manufacturing 97

Fierce Pharma

JANUARY 3, 2024

Morgan Healthcare Conference, attendees will get a chance to hear from AbbVie, Amarin and several other pharmaceutical companies. Morgan Healthcare Conference moves into its third day, we're covering the latest developments here. | On Wednesday at the the J.P.

Healthcare 317

Healthcare Healthcare Pharmaceutical 317

Fierce Pharma

JANUARY 18, 2024

It took 17 years for Sun Pharmaceutical and Taro Pharmaceutical to finally tie the knot. | It took 17 years for Sun Pharmaceutical and Taro Pharmaceutical to finally tie the knot. The deal nets out to $348 million for a 48% premium on Taro's share price of $29.

Pharmaceutical 246

Pharmaceutical 246

Fierce Pharma

JANUARY 8, 2024

Johnson & Johnson is starting the year with a new corporate identi | Despite all the recent changes at Johnson & Johnson, the company maintains an aggressive outlook for its pharmaceuticals division. In fact, J&J's sales forecasts for some drugs come in vastly higher than analyst numbers.

Sales 316

Sales Pharmaceutical 316

Fierce Pharma

FEBRUARY 12, 2024

billion buyout of rare disease specialist Reata Pharmaceuticals, the companies’ blockbuster bid for Reata’s Friedreich’s ataxia (FA) drug Skyclarys is starti | Roughly half a year after Biogen’s $7.3 Roughly half a year after Biogen’s $7.3

Pharmaceutical 264

Pharmaceutical 264

Fierce Pharma

MARCH 20, 2024

As two of the world’s largest pharmaceutical companies, Johnson & Johnson and Pfizer have long been rivals in various therapeutic areas. | The company is accusing former employee Andrew Brackbill of downloading thousands of confidential strategy-related files before leaving for rival Pfizer.

Pharmaceutical 306

Pharmaceutical 306

Fierce Pharma

AUGUST 13, 2024

Despite winning an FDA approval in 2023 and gaining clarity in May on the regulatory path forward for its Type 1 diabetes prospect sotagliflozin, Lexicon Pharmaceuticals hasn’t had an easy go of it | As part of a restructuring initiative, Lexicon Pharmaceuticals will lay off more than 75 staffers, or approximately 50% of its current field force, by (..)

Prospecting 264

Prospecting FDA Pharmaceutical 264

Fierce Pharma

JUNE 12, 2024

The ruling came in Teva's case against Amneal Pharmaceuticals, which is seeking to launch a generic version of the drug. . | A federal judge in New Jersey ruled that five of Teva’s patents on the metered dose inhaler for its asthma med ProAir HFA are “improperly listed” in the FDA’s Orange Book.

FDA 336

FDA Pharmaceutical 336

Fierce Pharma

OCTOBER 17, 2023

As Elevar Therapeutics and Hengrui Pharmaceuticals await an FDA decision on their combination therapy for newly diagnosed unresectable liver cancer—approved in China back in February—the partners a | As Elevar Therapeutics and Hengrui Pharmaceuticals await an FDA decision on their combination therapy for newly-diagnosed unresectable liver cancer—approved (..)

Marketing 289

Marketing FDA Pharmaceutical 289

Fierce Pharma

APRIL 3, 2024

Fifteen years after gaining its first FDA approval for Fanapt (iloperidone) to treat schizophrenia, Vanda Pharmaceuticals has scored again with the same antipsychotic drug. The FDA has signed off on Fanapt tablets to treat adults with manic or mixed episodes associated with bipolar I disorder.

FDA 264

FDA Pharmaceutical 264

Fierce Pharma

NOVEMBER 14, 2023

Pfizer plans to cut approximately 500 roles and ax its Pharmaceutical Sciences Small Molecule capabilities at its site in Sandwich in Kent in the U.K. Earlier this month, Pfizer’s $3.5 billion cost-cutting campaign crossed overseas to Ireland. Now, just a week later, Pfizer is announcing hundreds more job cuts in the U.K.

Pharmaceutical 355

Pharmaceutical 355

Fierce Pharma

NOVEMBER 29, 2023

. | Amgen is growing its decade-old collaboration with Amazon Web Services—a widely used cloud platform—to create generative artificial intelligence that the companies aim to use to increase the manufacturing throughput of pharmaceuticals.

Manufacturing 340

Manufacturing Medicine Pharmaceutical 340

Fierce Pharma

FEBRUARY 23, 2024

This week on “The Top Line,” we explore the impact of environmental, social and governance measures, commonly known as ESG, on the pharmaceutical industry. | This week on "The Top Line," we explore the impact of environmental, social, and governance measures, commonly known as ESG, on the pharmaceutical industry.

Government 262

Government Pharmaceutical Pharma 262

Fierce Pharma

SEPTEMBER 24, 2024

With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply chain. Vertex has inked a long-term supply agreement with Swiss CDMO Lonza to crank out global commercial supply of Casgevy.

Manufacturing 312

Manufacturing Pharmaceutical 312

Fierce Pharma

SEPTEMBER 29, 2023

A proposed restriction on the use of fluorinated substances in Europe would have an “irredeemable impact” on the continent’s life sciences sector, the European Federation of Pharmaceutical Industri | A proposed restriction on the use of fluorinated substances in Europe would have an “irredeemable impact” on the continent’s life sciences sector, the (..)

Manufacturing 279

Manufacturing Pharmaceutical 279

Fierce Pharma

DECEMBER 5, 2023

As Johnson & Johnson places a magnifying glass on its pharmaceutical business, the focus for the remainder of the decade rests on the shoulders of some 25 new and upcoming drugs.

Sales 312

Sales Pharmaceutical 312